Skip to main content
Premium Trial:

Request an Annual Quote

Barcelona's CGR Inks Collaboration with Illumina

NEW YORK (GenomeWeb News) – Barcelona's Centre for Genomic Regulation announced on Tuesday a one-year collaboration with Illumina.

The center provided few details about the collaboration and did not respond to a request for comment. In a statement, it said that the deal paves "the way for molecular medicine" and could transform healthcare.

"This is the first step in a joint working relationship, which I believe could be very fruitful, and which opens the door to more applied collaborations in the field of genomics, including the study of genetic diseases," Luis Serrano, CRG's director, said in the statement.

CRG said that the deal aligns with its strategy to foster collaboration between itself and commercial enterprises.

"These kinds of alliances, and partnerships with hospitals, other research institutes and patient associations, are exactly what the CRG hopes to foster, as they are essential in attracting private funding and the development of a new economic model based on knowledge and innovation," it said.

Earlier this month, the center announced a deal with Sanofi directed at research projects in medical genetics, epigenetics, and computational biology.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.